NICE set to decline RoActemra for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
The National Institute for health and Clinical Excellence looks set to reject Roche's first-in-class interleukin-6 inhibitor RoActemra (tocilizumab) for treating NHS patients in England and Wales with rheumatoid arthritis.